Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

Summary

This research study is a two stage study which consists of a safety run-in phase and a randomized phase 2 study which include subjects with previously-untreated, metastatic pancreatic adenocarcinoma. In the run-in safety study, the safety of adding two formulations (IV or Oral) of paricalcitol to a standard chemotherapy program of gemcitabine and nab-paclitaxel will be evaluated. The randomized phase 2 study will evaluate the efficacy of paricalcitol when added to gemcitabine and nab-paclitaxel The drugs involved in this study are: * Paricalcitol * Gemcitabine * Nab-paclitaxel

Timeline

Start

2018-12-05

Primary completion

2024-07-01

Completion

2024-07-01

Publications

• Perez KJ, Dias Costa A, Jordan A, Karasic TB, Elganainy D, Kim S, Yuan C, Gui DY, Tan R, Hong SC, Wang X, Cristea S, Coleman E, Truitt M, Oh TG, Zheng H, Furniss CS, Brais L, Bird A, Remland J, Gocheva V, Thalappillil JS, Anderson M, Cleary JM, Enzinger A, Giannakis M, Ng K, Rubinson DA, Schlechter B, Surana R, Singh H, Abrams T, Teitelbaum U, Izgur N, Allen E, Winter PS, Raghavan S, Yeh JJ, Von Hoff D, Liddle C, Downes M, Evans RM, O'Dwyer P, Aguirre A, Nowak JA, Wolpin BM. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Nat Cancer. 2026 Jun;7(6):928-943. doi: 10.1038/s43018-026-01165-8. Epub 2026 May 25.

Drugs

Indications